Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 4,173 | 615 | 3,515 |
| Samples | 845 | 191 | 645 |
| Peptides | 767 | 186 | 604 |
Function
UNC13B · Unc-13 homolog B
This gene is expressed in the kidney cortical epithelial cells and is upregulated by hyperglycemia. The encoded protein shares a high level of similarity to the rat homolog, and contains 3 C2 domains and a diacylglycerol-binding C1 domain. Hyperglycemia increases the levels of diacylglycerol, which has been shown to induce apoptosis in cells transfected with this gene and thus contribute to the renal cell complications of hyperglycemia. Studies in other species also indicate a role for this protein in the priming step of synaptic vesicle exocytosis. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
6 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000635942 | A0A1B0GUS7* | 920 | 673 |
| ENST00000619578 | O14795-2 | 744 | 548 |
| ENST00000396787 | B1AM27* | 732 | 539 |
| ENST00000378495 | O14795 | 722 | 531 |
| ENST00000636694 | A0A1B0GVW8* | 548 | 406 |
| ENST00000617908 | A0A087X1S8* | 507 | 372 |
Gene Properties
Recurrent Mutations
All 548 amino-acid changes on canonical ENST00000619578 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in UNC13B · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in UNC13B – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 4/40 10% | 0/0 0% |
| T-Cell Non-Hodgkins Lymphoma | 2/26 8% | 0/0 0% |
| Endometrial Carcinoma | 12/42 29% | 37/612 6% |
| Glioblastoma | 5/98 5% | 0/0 0% |
| Melanoma | 19/210 9% | 80/1899 4% |
| Acute Myeloid Leukemia | 4/90 4% | 0/0 0% |
| Hodgkins Lymphoma | 3/16 19% | 2/122 2% |
| Non-Small Cell Lung Carcinoma | 23/304 8% | 36/1390 3% |
| Gastric Carcinoma | 5/74 7% | 54/1809 3% |
| Cervical Carcinoma | 1/35 3% | 13/422 3% |
| Neuroendocrine Tumour | 11/154 7% | 10/577 2% |
| Colorectal Carcinoma | 23/143 16% | 72/3239 2% |
| Bladder Carcinoma | 1/58 2% | 27/956 3% |
| Thymic Epithelial Tumor | 0/0 0% | 1/39 3% |
| Squamous Cell Lung Carcinoma | 3/57 5% | 19/810 2% |
| Burkitts Lymphoma | 5/32 16% | 0/196 0% |
| Other Solid Cancers | 3/94 3% | 31/1515 2% |
| Germ Cell Tumour | 2/25 8% | 2/169 1% |
| Plasma Cell Myeloma | 5/44 11% | 2/305 1% |
| Rhabdomyosarcoma | 2/33 6% | 2/171 1% |
| Ovarian Carcinoma | 10/109 9% | 11/998 1% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Other Sarcomas | 5/69 7% | 8/699 1% |
| Hepatocellular Carcinoma | 3/46 7% | 29/2210 1% |
| Pheochromocytoma and Paraganglioma | 0/0 0% | 1/71 1% |
| Esophageal Squamous Cell Carcinoma | 3/51 6% | 31/2550 1% |
| Biliary Tract Carcinoma | 0/54 0% | 13/950 1% |
| Kidney Carcinoma | 6/85 7% | 19/1862 1% |
| Head and Neck Carcinoma | 4/85 5% | 16/1574 1% |
| Esophageal Carcinoma | 0/23 0% | 9/769 1% |
Mutation Distribution
Where UNC13B is mutated · all tissues, split by cell line vs tissue
How many mutations in UNC13B were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 4,173 mutations in UNC13B
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|